Jun. 10 at 1:56 AM
$GSK signed a definitive agreement to acquire
$NUVL for
$10.6B cash. GSK will launch a tender offer within 10 business days to buy all outstanding Class A & Class B common stock at
$124/share in cash
GSK looks to expand its pipeline of lung cancer therapies - includes 2 late-stage, potential best-in-class ROS1 (zidesamtinib) & ALK (neladalkib) inhibitors for non-small cell lung cancer (NSCLC), currently under US FDA review for 2026 approvals. Accelerates entry into lung cancer, providing a platform for expansion with Ris-Rez, GSKâs B7-H3 antibody-drug conjugate (ADC)
Acquisition expected to be accretive to sales & core op profit in FY27 & core EPS in FY29 inclusive of synergies & reprioritisation. Expect low single-digit percentage dilution to core EPS for the current year, FY 2027 and FY 2028.
Transaction is expected to close in 3Q26, subject to antitrust clearance & a majority tender of shares
Leerink Partners LLC &
$C are acting as financial advisors for GSK
$JEF serving as financial advisor for Nuvalent
Nuvalent break-up fee
$350.475M
